Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Number of participants receiving new therapy based on study findings
研究概览
简要总结
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
详细描述
This study supports the collection of tumor specimens for CLIA-certified genomic testing and research testing in parallel. CLIA-certified tests have established measurements of accuracy and precision which allow for return of results. This study does not involve treatment, only testing, which could be used to meet eligibility criteria in other trials or therapies. This study includes a registry for longitudinal evaluation of patients whose cancer has FGFR mutations such as cholangiocarcinoma, pancreatic cancer, and others (telehealth).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A histologically or cytologically confirmed diagnosis of cancer
- •Patients with any malignancy.
- •Patients must have tumor suitable for research tumor biopsy (as assessed by trained specialists in interventional radiology) and Patients are medically fit to undergo a tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a tumor suitable for biopsy but have another tissue available for molecular evaluation.
- •OR Patients are undergoing standard of care surgeries or procedures where fresh specimens will be first used for routine pathologic assessment and only then will leftover tissue be used for research purposes.
- •Procedure-specific signed informed consent prior to initiation of any study-related procedures.
- •Women and minorities are included in this protocol.
- •Patients with multiple malignancies remain eligible.
- •Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible.
排除标准
- •It is the enrolling study physicians discretion to decide if a patient is not fit enough to undergo tissue biopsy.
- •Patients who are incarcerated are not eligible to participate.
结局指标
主要结局
Number of participants receiving new therapy based on study findings
时间窗: Up to 24 Months
Impact on clinical care
次要结局
- Average number of days to return results(Up to 24 months)
研究者
Sameek Roychowdhury
Principal Investigator
Ohio State University Comprehensive Cancer Center